Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
Kymera Therapeutics (NASDAQ:KYMR) announced a major licensing deal with Gilead Sciences to develop novel oral molecular glue CDK2 degraders for oncology treatments. The agreement includes potential payments of up to $750 million, comprising $85 million in upfront and option exercise payments, plus tiered royalties ranging from high single-digit to mid-teens on net sales.
Kymera will lead research activities for the CDK2 program, while Gilead gains global rights to develop, manufacture, and commercialize resulting products upon exercising its option. The collaboration targets breast cancer and other solid tumors, representing a significant expansion of Kymera's therapeutic pipeline.
Kymera Therapeutics (NASDAQ:KYMR) announced a major licensing deal with Gilead Sciences to develop novel oral molecular glue CDK2 degraders for oncology treatments. The agreement includes potential payments of up to $750 million, comprising $85 million in upfront and option exercise payments, plus tiered royalties ranging from high single-digit to mid-teens on net sales.
Kymera will lead research activities for the CDK2 program, while Gilead gains global rights to develop, manufacture, and commercialize resulting products upon exercising its option. The collaboration targets breast cancer and other solid tumors, representing a significant expansion of Kymera's therapeutic pipeline.